5VA.F VAXCYTE INC. DL -001

Healthcare Biotechnology Frankfurt Exchange
57.00 EUR
Close of Nov 11, 2026
34.80 65.00
Market cap
EUR 9.02B
P/E
-
P/B
4.07x
ROE
-48.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 5VA.F undervalued?

Graham number

The Graham number of VAXCYTE INC. DL -001 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

VAXCYTE INC. DL -001 fundamental analysis

No fundamental analysis for VAXCYTE INC. DL -001 yet.

VAXCYTE INC. DL -001 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About VAXCYTE INC. DL -001

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; …

Full company profile